Effect of supervised training on FEV1 in cystic fibrosis: A randomised controlled trial Susi Kriemler, Stephanie Kieser, Sibylle Junge, Manfred Ballmann,

Slides:

Advertisements

Similar presentations

Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis Giuseppe Valenza, Dennis Tappe, Doris.

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

Zhumin Zhang, Suzanne M. Shoff, HuiChuan J. Lai

Infections in Patients with Cystic Fibrosis

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

William G. Flight, Jonathan Shaw, Susan Johnson, A

Abaigeal D. Jackson, Christopher H. Goss Journal of Cystic Fibrosis

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy Edith T. Zemanick, J. Kirk Harris,

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Patrick O. Sobande, James D. Acton, Raouf S. Amin, Jeanne Weiland

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

David N. Sheppard Journal of Cystic Fibrosis

John Widger, Sarath Ranganathan, Philip J. Robinson

Pulmonary exacerbations in CF patients with early lung disease

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state Bradley.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Claire Keating, Armeen D

Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis Diana Bilton, Gabriel Bellon, Brett Charlton, Peter Cooper,

Vitamin A and lung function in CF

The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation Verena I. Seliger, David Rodman, Fredrick Van.

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients Drucy Borowitz, Christopher Stevens,

Thomas Radtke, Milo A. Puhan, Helge Hebestreit, Susi Kriemler

Asians with cystic fibrosis in the UK have worse disease outcomes than clinic matched white homozygous ΔF508 controls Jonathan McCormick, Simon A. Ogston,

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis Manfred Ballmann, Horst von der Hardt

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Physiologic endpoints for clinical studies for cystic fibrosis

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Valerie Waters, Eshetu G

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Calculation of the capnographic index based on expiratory molar mass–volume-curves — A suitable tool to screen for cystic fibrosis lung disease Susanne.

Cytokine gene polymorphisms and severity of CF lung disease

Nasal polyposis in lung transplant recipients with cystic fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Lung clearance index during hospital admission in school-age children with cystic fibrosis Liam Welsh, Christopher Nesci, Haily Tran, Marisol Tomai,

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation Markus Hofer, Christoph Schmid, Christian Benden, Rudolf Speich,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale,

Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis Giuseppe Valenza, Dennis Tappe, Doris.

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Anne K. Swisher, Kathryn Moffett, Linda Baer

Absence of a gender gap in survival

Cystic fibrosis and pregnancy in the modern era: A case control study

Presentation transcript:

Effect of supervised training on FEV1 in cystic fibrosis: A randomised controlled trial Susi Kriemler, Stephanie Kieser, Sibylle Junge, Manfred Ballmann, Alexandra Hebestreit, Christian Schindler, Christoph Stüssi, Helge Hebestreit Journal of Cystic Fibrosis Volume 12, Issue 6, Pages 714-720 (December 2013) DOI: 10.1016/j.jcf.2013.03.003 Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Flow of participants. Flow of individual participants through study, with outcome measures. Journal of Cystic Fibrosis 2013 12, 714-720DOI: (10.1016/j.jcf.2013.03.003) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Changes in FEV1 in both training groups vs. controls. Change in forced expiratory volume in 1s (FEV1[%predicted], from baseline to 24months in the aerobic training group (AT), strength training group (ST), the Swiss (CONCH) and German (COND) control groups. The primary outcome, i.e. the change in FEV1 after 6months, is highlighted. Data are presented as means±95%CI. Adjustments were done for age, sex and FEV1 baseline value. CONCH versus ST (a) and AT (b), COND versus ST(c) and AT (d); one symbol denotes p<0.05, two symbols p<0.01, three symbols p<0.001. Journal of Cystic Fibrosis 2013 12, 714-720DOI: (10.1016/j.jcf.2013.03.003) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Changes in lung function in both training groups vs. controls. Change in lung function (FVC [%predicted] and RV/TLC[%]) and aerobic performance (VO2peak [ml∗kg−1∗min−1], Watts [W∗kg−1] from baseline to 24months in the aerobic training group (AT) and strength training group (ST) compared with the Swiss (CONCH) and German (COND) control groups. Data are presented as means±95%CI. All outcomes were adjusted for age, sex, the respective baseline value, VO2peak and Watts additionally for skinfolds and fat free mass. CONCH versus ST (a) and AT (b), COND versus ST(c) and AT (d); one symbol denotes p<0.05, two symbols p<0.01, three symbols p<0.001. Journal of Cystic Fibrosis 2013 12, 714-720DOI: (10.1016/j.jcf.2013.03.003) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Long-term changes of FEV1 in controls vs. CF registry data. Decline of forced expiratory volume in 1s (FEV1) in both CF control groups compared with Swiss (REGCH, n=35) and German (REGD, n=701) cystic fibrosis registry data (only patients with CF older than 12years and with an FEV1>35% were included, participants of the CONCH and COND were excluded). Data are presented as means±SE. Adjustments were done for age and sex. Journal of Cystic Fibrosis 2013 12, 714-720DOI: (10.1016/j.jcf.2013.03.003) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions